JCVI backs immediate expansion of COVID-19 vaccination to combat Omicron variant

The COVID-19 booster campaign should expand immediately to people aged 18-39 and second doses should be offered to those aged 12-15, under JCVI advice updated in response to the Omicron variant.

JCVI COVID-19 immunisation chair Professor Wei Shen Lim (Photo: JustinTallis/Getty Images)

Updated advice from the Joint Committee on Vaccination and Immunisation (JCVI) says eligibility for booster doses of COVID-19 vaccine should expand immediately to all adults aged 18 to 39 years old.

The updated advice says booster vaccination - with either the Pfizer or Moderna vaccines - should continue to be rolled out 'in order of descending age groups' and prioritising those in at-risk groups, but shortens the timescale within which booster doses can be offered.

Plans to expand the booster campaign come as GP leaders appeal to ministers to reduce administrative pressure on general practice to allow a greater focus on the vaccination campaign.

COVID-19 booster vaccination

Booster doses should not be given 'within three months of completion of the primary course' of COVID-19 vaccination, the advice says - halving the previous recommendation that boosters should take place six months after primary vaccination.

Patients with severe immunosuppression who have received three doses as part of their primary course can also be offered a booster jab three months after their third dose.

The JCVI has also recommended that all children and young people aged 12 to 15 years old should be offered a second dose of the Pfizer COVID-19 vaccine 'at a minimum of 12 weeks from the first dose'.

It said that a reduction in the interval to eight weeks could be approved 'if the emerging epidemiological data supports this' - and that this shorter timeframe could also be applied for 16- to 17-year-olds.

A statement from the committee said: 'The overall intention of the measures advised above is to accelerate the deployment of COVID-19 vaccines before the peak of any impending Omicron wave.

Omicron infection

'There is currently no data to indicate that Omicron infection is associated with a change in the pattern of susceptibility to serious COVID-19 (hospitalisation and death). Persons of older age, or who are in COVID-19 at-risk groups are likely to remain at higher risk from serious COVID-19; therefore, vaccination should be prioritised accordingly.

'Continued efforts should be made to offer COVID-19 vaccination (first, second and booster doses) to adults who have yet to receive any COVID-19 vaccinations.'

Deputy CMO Professor Jonathan Van Tam told a Downing Street press conference: 'We don't know what is going to happen next. The next three weeks will be weeks of scientific uncertainty.

'While we wait for the mist to clear on what this concerning variant means, there is no time to delay. Vaccine boosting is the thing we can do most easily while we wait for the science mist to clear.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us:

Just published

NHS prescription and packet of pills

GPs can now prescribe flu antivirals on the NHS

GPs and other prescribers are now able to issue NHS prescriptions for antivirals...

GP sign

Prevention set to be key battleground for 2024 GP contract

Negotiations on a new GP contract from 2024/25 will need to 'align closely' with...

Talking General Practice logo

Podcast: What makes a strong PCN and how will integrated care systems affect networks?

Talking General Practice speaks to GP and PCN clinical director Professor Aruna Garcea,...


GP core funding rise outstripped by staff pay awards under five-year contract

Staff pay awards have outstripped increases in core GP practice funding between 2019/20...

BMA sign

Fifth of GP time spent on non-medical work as NHS absorbs cost of 'government failure'

Doctors are 'picking up the pieces of government failures' as the cost-of-living...


How the five fundamentals of COPD care can help GPs support patients

GP Dr Andrew Whittamore, clinical lead at Asthma + Lung UK, explains NICE’s five...